Hindustan Bio Sciences
- Market cap
- ₹ 7 Cr.
- P/E
- 62.2x
- P/B
- 8.66x
- 52-week range
- 5 – 9.92
- ROE
- −9%
- ROCE
- −2.4%
- Dividend yield
- 0%
- Debt / equity
- 2.84
- Sector
- IT - Software
- Industry
- Software Products
- Listed on
- BSE
About
Hindustan Bio Sciences Limited is an India-based company, which is engaged in the manufacturing and sale of pharmaceutical products. The Company is involved in the trading of drugs and medicine. The Company has manufacturing facilities for dry and liquid injectables, liquid/dry syrups, eye/ear/nasal drops, pre-filled syringes and non-sterile/sterile ointments, tablets, and capsules. Its products include tablets, capsules, drops, externels, and syrups.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Software Products: 58 companies →Hindustan Bio Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)62.2 against a typical 32.6: pricier than most peers (1st = cheapest).42nd of 58
- Sales growth−100% against a typical +16.4% from a year earlier.40th of 46
- Profit growth−1,200% against a typical −14.3% from a year earlier.37th of 39
- Share price, 3 months−0.4% against a typical −7.6%.14th of 51
- Size₹ 7.1 Cr. market value against a typical ₹ 59.8 Cr. (1st = largest).45th of 56
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | −0 | −0 |
| OPM % | 18.8% | 18.8% | 10.3% | 17.1% | 17.1% | — | 26.3% | 0% | — | 18.4% | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | −0 | −0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | −0 | −0 |
| EPS in Rs | 0.07 | 0.07 | 0.04 | 0.08 | 0.08 | −0.04 | 0.11 | 0.01 | −0.06 | 0.08 | −0.12 | −0.11 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −5%
- 5 Years
- −6%
- 3 Years
- −7%
- TTM
- −66%
- 10 Years
- 4%
- 5 Years
- 14%
- 3 Years
- —
- TTM
- −231%
- 10 Years
- 13%
- 5 Years
- 16%
- 3 Years
- 2%
- TTM
- —
- 10 Years
- −22%
- 5 Years
- −11%
- 3 Years
- 3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Hindustan Bio Sciences | ₹ 6.80 | ₹ 7 Cr. | 62.2x | 8.7x | −9% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Venkata Rama Mohan Raju Jampana
- Executive Chairman of the Board, Managing Director
- Jaison George
- Chief Financial Officer, Director
- Shailendra Vyas
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.